{"hands_on_practices": [{"introduction": "At the heart of most sensitive molecular diagnostic assays, including many CRISPR-based platforms, lies a pre-amplification step like PCR. This initial practice focuses on the fundamental principle of exponential amplification, which is the engine that drives a minuscule amount of target nucleic acid to detectable levels. Mastering this core calculation [@problem_id:4620588] is essential for estimating an assay's theoretical limits and understanding the relationship between starting material, reaction efficiency, and the number of cycles required to obtain a positive signal.", "problem": "A Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based fluorescence assay using CRISPR-associated (Cas) enzymes is coupled to a pre-amplification step by quantitative polymerase chain reaction (PCR). In this workflow, a trans-cleavage fluorescence signal becomes reliably detectable once the number of target amplicon molecules in the reaction reaches a threshold of $10^{9}$ molecules. The pre-amplification proceeds in discrete cycles with a constant per-cycle efficiency $E$, defined as the fractional increase in amplicon count per cycle under conditions where reaction components are not limiting and degradation is negligible. Assume that each cycle multiplies the current number of amplicons by a factor of $1+E$, independently of other cycles. The initial template count is $N_{0}=5$ copies, and the efficiency is $E=0.95$. Determine the smallest integer number of cycles $n$ required for the amplicon count to meet or exceed $10^{9}$. Report the minimum integer $n$ that satisfies this requirement.", "solution": "The problem statement is deemed valid as it is scientifically grounded, well-posed, objective, and contains all necessary information to derive a unique solution.\n\nThe process of polymerase chain reaction (PCR) amplification is modeled as exponential growth over discrete cycles. Let $N_n$ be the number of amplicon molecules after $n$ cycles. The initial number of template molecules is given as $N_0$. The problem states that each cycle multiplies the current number of amplicons by a factor of $1+E$, where $E$ is the per-cycle efficiency. Therefore, the number of molecules after $n$ cycles can be expressed by the geometric progression:\n$$N_n = N_0 (1+E)^n$$\n\nThe given values are:\n- Initial template count: $N_0 = 5$\n- Per-cycle efficiency: $E = 0.95$\n- Detection threshold: $N_{th} = 10^9$ molecules\n\nThe condition for the fluorescence signal to be reliably detectable is that the number of amplicon molecules, $N_n$, must meet or exceed the threshold $N_{th}$. This can be written as the inequality:\n$$N_n \\ge N_{th}$$\n\nSubstituting the expression for $N_n$ and the given values into this inequality, we obtain:\n$$5 (1 + 0.95)^n \\ge 10^9$$\n$$5 (1.95)^n \\ge 10^9$$\n\nTo solve for the number of cycles $n$, we first isolate the term containing the exponent. We divide both sides of the inequality by $5$:\n$$(1.95)^n \\ge \\frac{10^9}{5}$$\n$$(1.95)^n \\ge 2 \\times 10^8$$\n\nNext, we take the natural logarithm, $\\ln$, of both sides. Since the natural logarithm is a monotonically increasing function, the direction of the inequality is preserved.\n$$\\ln((1.95)^n) \\ge \\ln(2 \\times 10^8)$$\n\nUsing the logarithm property $\\ln(x^y) = y \\ln(x)$, we can bring the exponent $n$ down:\n$$n \\ln(1.95) \\ge \\ln(2 \\times 10^8)$$\n\nSince $1.95 > 1$, its natural logarithm $\\ln(1.95)$ is a positive number. Therefore, we can divide both sides by $\\ln(1.95)$ without changing the direction of the inequality:\n$$n \\ge \\frac{\\ln(2 \\times 10^8)}{\\ln(1.95)}$$\n\nUsing the logarithm property $\\ln(a \\times b) = \\ln(a) + \\ln(b)$, the numerator can be expanded:\n$$n \\ge \\frac{\\ln(2) + \\ln(10^8)}{\\ln(1.95)}$$\n$$n \\ge \\frac{\\ln(2) + 8 \\ln(10)}{\\ln(1.95)}$$\n\nNow, we must evaluate this expression to find the minimum value for $n$.\n$$n \\ge \\frac{\\ln(200000000)}{\\ln(1.95)}$$\nUsing numerical values for the logarithms:\n$$n \\ge \\frac{19.113829...}{0.667829...}$$\n$$n \\ge 28.6214...$$\n\nThe problem asks for the smallest integer number of cycles $n$. Since $n$ must be an integer and must be greater than or equal to $28.6214...$, the smallest integer that satisfies this condition is the next highest integer, which is obtained by taking the ceiling of the value.\n$$n = \\lceil 28.6214... \\rceil = 29$$\n\nTherefore, a minimum of $29$ cycles are required for the amplicon count to reach or exceed the detection threshold of $10^9$ molecules.\nWe can verify this result:\nFor $n=28$: $N_{28} = 5 \\times (1.95)^{28} \\approx 5 \\times (1.439 \\times 10^8) \\approx 7.20 \\times 10^8$, which is less than $10^9$.\nFor $n=29$: $N_{29} = 5 \\times (1.95)^{29} \\approx 5 \\times (2.806 \\times 10^8) \\approx 1.40 \\times 10^9$, which is greater than $10^9$.\nThe calculation is confirmed.", "answer": "$$\\boxed{29}$$", "id": "4620588"}, {"introduction": "While understanding ideal amplification is crucial, a real-world laboratory environment presents challenges like low-level contamination. This next exercise [@problem_id:4620581] moves from theory to practice by addressing how to interpret and quantify the signal from a No-Template Control (NTC). By applying the same exponential growth model in reverse, you will learn to estimate the level of contaminant from its cycle threshold ($C_t$) and use this data to make a critical decision: whether an experimental batch meets the quality criteria to be considered valid.", "problem": "A Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas12a assay coupled to quantitative Polymerase Chain Reaction (qPCR) is being validated for detection of a pathogen-associated nucleic acid in clinical specimens. In this platform, the pre-amplification stage is an idealized exponential process with per-cycle amplification efficiency $E$ taken to be $E=1.0$, meaning the target copy number doubles each cycle. The fluorescence threshold is crossed when the amplicon count reaches a fixed, assay-specific threshold $N_{\\text{thr}}$ that is stable across runs. A calibration experiment performed immediately before the validation used a plasmid standard with initial copy number $N_{\\text{cal}}=10^{3}$ copies per reaction, and its cycle threshold (Ct; the cycle at which fluorescence crosses the threshold) was observed at $C_{\\text{cal}}=30$ cycles.\n\nDuring the current validation batch, the No-Template Control (NTC) wells showed late amplification in $2/24$ wells at cycle $C_{\\text{NTC}}=38$. Assume that any well without amplification has $0$ detectable contaminant copies, and that the late-amplifying NTC wells have identical contamination levels that can be inferred from their Ct using the calibration and the ideal exponential amplification model.\n\nUsing only the above information and first principles of exponential amplification, estimate the mean contamination level across the batch in copies per reaction. Round your answer to three significant figures and express the result in copies per reaction. Separately, determine whether the batch passes the following acceptance criteria: the fraction of NTC wells exhibiting amplification must be less than $0.10$, and the mean contamination must be less than or equal to $0.50$ copies per reaction. Provide your numerical contamination estimate as the final answer.", "solution": "The problem statement is first subjected to a rigorous validation process.\n\n**Step 1: Extract Givens**\n-   Assay platform: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas12a with quantitative Polymerase Chain Reaction (qPCR) pre-amplification.\n-   Amplification model: Idealized exponential process.\n-   Per-cycle amplification efficiency: $E = 1.0$.\n-   Fluorescence threshold amplicon count: $N_{\\text{thr}}$ (fixed and stable).\n-   Calibration standard initial copy number: $N_{\\text{cal}} = 10^3$ copies per reaction.\n-   Calibration standard cycle threshold: $C_{\\text{cal}} = 30$ cycles.\n-   No-Template Control (NTC) results: $2$ out of $24$ wells showed amplification.\n-   NTC cycle threshold for late-amplifying wells: $C_{\\text{NTC}} = 38$ cycles.\n-   Assumption for non-amplifying NTCs: $0$ detectable contaminant copies.\n-   Assumption for amplifying NTCs: Identical contamination levels.\n-   Acceptance Criterion 1: Fraction of NTC wells with amplification $< 0.10$.\n-   Acceptance Criterion 2: Mean contamination $\\le 0.50$ copies per reaction.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is assessed for validity against the established criteria.\n-   **Scientifically Grounded**: The problem is based on the fundamental principles of qPCR. The model of exponential amplification, $N_C = N_0(1+E)^C$, is the standard theoretical basis for qPCR quantification. The use of $E=1.0$ represents an ideal 100% efficiency, a common simplification for theoretical problems. The use of calibration standards and No-Template Controls (NTCs) to determine unknown quantities and assess contamination, respectively, is standard laboratory practice in molecular diagnostics. The relationship between the initial template concentration and the cycle threshold ($C_t$) is the core of quantitative analysis. The scenario of low-level contamination appearing as late amplification in NTCs is a realistic and common challenge.\n-   **Well-Posed**: The problem is self-contained and provides all necessary data to derive a unique solution. The values for initial copy numbers and cycle thresholds for both the standard and the NTCs are provided, allowing for the calculation of the contaminant copy number. The total number of NTCs and the number of contaminated NTCs are specified, enabling the calculation of the mean contamination level. The acceptance criteria are explicitly and quantitatively defined.\n-   **Objective**: The problem is stated using precise, objective, and quantitative terms (e.g., $E=1.0$, $N_{\\text{cal}}=10^3$, $C_{\\text{cal}}=30$). There is no reliance on subjective or ambiguous language.\n\nThe problem does not violate any of the invalidity conditions. It is scientifically sound, well-posed, and objective.\n\n**Step 3: Verdict and Action**\nThe problem is deemed **valid**. A complete, reasoned solution will be provided.\n\n**Solution Derivation**\nThe pre-amplification stage is described as an idealized exponential process. The number of target nucleic acid copies, $N_C$, after $C$ cycles of amplification is given by the formula:\n$$N_C = N_0(1+E)^C$$\nwhere $N_0$ is the initial number of copies and $E$ is the per-cycle amplification efficiency.\nThe problem states that the efficiency $E = 1.0$, which corresponds to a perfect doubling of the target sequence in each cycle. The formula thus simplifies to:\n$$N_C = N_0 \\cdot 2^C$$\nThe cycle threshold, denoted as $C_t$, is the cycle number at which the fluorescence signal crosses a predefined threshold. This corresponds to the point where the number of amplicons, $N_C$, reaches a fixed value, $N_{\\text{thr}}$. Therefore, for any given reaction, the initial copy number $N_0$ and its corresponding cycle threshold $C_t$ are related by:\n$$N_{\\text{thr}} = N_0 \\cdot 2^{C_t}$$\nSince $N_{\\text{thr}}$ is an assay-specific constant, we can establish a relationship between two different reactions (e.g., a calibrator and a sample) by equating their expressions for $N_{\\text{thr}}$.\n\nFirst, we apply this relationship to the calibration standard:\n$$N_{\\text{thr}} = N_{\\text{cal}} \\cdot 2^{C_{\\text{cal}}}$$\nNext, we apply the same relationship to the late-amplifying NTC wells, which contain an unknown number of contaminant copies, $N_{\\text{contam}}$:\n$$N_{\\text{thr}} = N_{\\text{contam}} \\cdot 2^{C_{\\text{NTC}}}$$\nBy equating the two expressions for $N_{\\text{thr}}$, we get:\n$$N_{\\text{cal}} \\cdot 2^{C_{\\text{cal}}} = N_{\\text{contam}} \\cdot 2^{C_{\\text{NTC}}}$$\nWe can now solve for $N_{\\text{contam}}$, the number of contaminant copies in each of the positive NTC wells:\n$$N_{\\text{contam}} = N_{\\text{cal}} \\cdot \\frac{2^{C_{\\text{cal}}}}{2^{C_{\\text{NTC}}}} = N_{\\text{cal}} \\cdot 2^{C_{\\text{cal}} - C_{\\text{NTC}}}$$\nSubstituting the given values, $N_{\\text{cal}} = 10^3$, $C_{\\text{cal}} = 30$, and $C_{\\text{NTC}} = 38$:\n$$N_{\\text{contam}} = 10^3 \\cdot 2^{30 - 38} = 10^3 \\cdot 2^{-8}$$\nCalculating the value of $2^{-8}$:\n$$2^8 = 256$$\n$$2^{-8} = \\frac{1}{256}$$\nTherefore, the number of contaminant copies in each of the two amplifying NTC wells is:\n$$N_{\\text{contam}} = \\frac{1000}{256} = 3.90625 \\text{ copies}$$\nThe problem asks for the mean contamination level across the entire batch of $24$ NTC wells. We are given that $2$ wells exhibited amplification (and thus contain $N_{\\text{contam}}$ copies each), and the remaining $24 - 2 = 22$ wells had no amplification and are assumed to contain $0$ contaminant copies.\nThe mean contamination level per reaction, $\\bar{N}_{\\text{contam}}$, is the total number of contaminant copies in all NTC wells divided by the total number of NTC wells:\n$$\\bar{N}_{\\text{contam}} = \\frac{(2 \\cdot N_{\\text{contam}}) + (22 \\cdot 0)}{24} = \\frac{2 \\cdot N_{\\text{contam}}}{24} = \\frac{N_{\\text{contam}}}{12}$$\nSubstituting the value of $N_{\\text{contam}}$:\n$$\\bar{N}_{\\text{contam}} = \\frac{3.90625}{12} \\approx 0.32552083...$$\nThe problem requires this result to be rounded to three significant figures.\n$$\\bar{N}_{\\text{contam}} \\approx 0.326 \\text{ copies per reaction}$$\n\n**Assessment against Acceptance Criteria**\nSeparately, we must determine if the validation batch passes the two specified acceptance criteria.\n\n1.  **Criterion 1**: The fraction of NTC wells exhibiting amplification must be less than $0.10$.\n    The fraction of amplifying NTCs is the number of positive wells ($2$) divided by the total number of NTC wells ($24$):\n    $$\\text{Fraction} = \\frac{2}{24} = \\frac{1}{12} \\approx 0.0833$$\n    Since $0.0833 < 0.10$, the batch **passes** this criterion.\n\n2.  **Criterion 2**: The mean contamination must be less than or equal to $0.50$ copies per reaction.\n    Our calculated mean contamination is $\\bar{N}_{\\text{contam}} \\approx 0.326$ copies per reaction.\n    Since $0.326 \\le 0.50$, the batch **passes** this criterion.\n\nThe final answer requested is the numerical estimate of the mean contamination level.", "answer": "$$\\boxed{0.326}$$", "id": "4620581"}, {"introduction": "Beyond individual calculations and quality checks lies the holistic design of a robust and reproducible experiment. This final practice [@problem_id:4620535] challenges you to act as a peer reviewer, using the internationally recognized Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines to critique a proposed qPCR assay. This exercise will sharpen your ability to identify the subtle but critical details—from amplification efficiency reporting to reference gene validation—that distinguish a preliminary finding from a quantitatively rigorous and defensible result.", "problem": "A clinical laboratory proposes a quantitative polymerase chain reaction (qPCR) assay to measure severe acute respiratory syndrome coronavirus $2$ (SARS-CoV-$2$) RNA load in nasopharyngeal swabs and to compare relative host gene expression responses during infection. The description states that primer sequences and amplicon length were validated in silico against human and viral genomes, reverse transcription was performed with random hexamers, and amplification was run for $40$ cycles at $60\\,^\\circ\\mathrm{C}$ annealing using a generic intercalating dye. The report claims linearity with coefficient of determination $R^2 \\ge 0.99$ for a plasmid-based standard curve generated by $10$-fold serial dilutions, and it normalizes host gene expression to glyceraldehyde-$3$-phosphate dehydrogenase (GAPDH). The assay includes a no-template control and a melt curve to check specificity. As an orthogonal check, the laboratory also ran a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated protein 12a (Cas12a) fluorescence assay targeting the same viral gene and observed concordant positive/negative calls, but did not use CRISPR signal for quantitation.\n\nYou are asked to critique the description using the Minimum Information for Publication of Quantitative Real-Time Polymerase Chain Reaction Experiments (MIQE) guidelines, focusing on elements that, if missing or unverified, can bias absolute or relative quantitation. Base your reasoning on the exponential nature of polymerase chain reaction amplification, the definition of the quantification cycle (Cq), and the log-linear relationship between input template amount and Cq within the validated dynamic range. Consider the effects of reaction efficiency, standard curve coverage, and reference gene stability on quantitative inference in infectious disease samples, which may contain inhibitors and exhibit infection-induced transcriptional changes.\n\nWhich of the following omissions or practices in the proposed description are most likely to bias the reported viral load or relative expression quantitation, according to MIQE?\n\nA. Failure to report the amplification efficiency and the slope of the standard curve, precluding assessment and correction for efficiency differences across runs or targets.\n\nB. Absence of an explicit statement of the dynamic range and the concentration points used to construct the standard curve, increasing the risk that sample Cq values are extrapolated outside the validated linear range.\n\nC. Use of a single unvalidated reference gene (GAPDH) for normalization in infected swab samples without demonstrating its expression stability under infection and treatment conditions.\n\nD. Lack of a no-reverse-transcriptase control to rule out genomic deoxyribonucleic acid (DNA) contribution when quantifying ribonucleic acid (RNA) targets.\n\nE. Failure to state the thermal cycler manufacturer and model used.\n\nF. Not reporting the CRISPR Cas12a trans-cleavage rate or fluorescence threshold used in the orthogonal assay.\n\nSelect all that apply.", "solution": "The validity of the problem statement is confirmed. It is scientifically grounded, well-posed, and objective, presenting a realistic scenario for critical evaluation based on established molecular biology principles and guidelines (MIQE). The task is to identify significant omissions in a described qPCR assay protocol that would likely bias quantitative results. This requires applying the fundamental theory of polymerase chain reaction.\n\nThe core principle of quantitative polymerase chain reaction (qPCR) is the exponential amplification of a deoxyribonucleic acid (DNA) target. The number of amplicon molecules, $N_c$, after $c$ cycles of amplification is given by the equation:\n$$ N_c = N_0 \\times E^c $$\nwhere $N_0$ is the initial number of target molecules and $E$ is the amplification efficiency per cycle (where an ideal reaction has $E=2$, representing a doubling of product in each cycle, and in practice $1 \\le E \\le 2$).\n\nThe quantification cycle, Cq, is defined as the cycle number at which the fluorescence from the accumulating product crosses a set threshold. At this cycle, the amount of product, $N_{Cq}$, is constant for all reactions being compared. Thus:\n$$ N_{Cq} = N_0 \\times E^{Cq} $$\nTaking the logarithm of this equation and rearranging to solve for Cq gives a linear relationship between Cq and the logarithm of the initial template amount, $\\log(N_0)$:\n$$ Cq = -\\frac{1}{\\log(E)} \\log(N_0) + \\frac{\\log(N_{Cq})}{\\log(E)} $$\nThis equation is in the form of a line, $y = mx + b$, where $y=Cq$, $x = \\log(N_0)$, and the slope is $m = -1/\\log(E)$.\n\n**Absolute quantitation** relies on a standard curve, a plot of Cq versus $\\log(N_0)$ for a series of standards with known concentrations. The concentration of an unknown sample is then interpolated from this curve. **Relative quantitation** compares the expression of a target gene to a stable reference (housekeeping) gene to normalize for variations in sample input and quality. The validity of both methods depends critically on several factors which must be reported according to the Minimum Information for Publication of Quantitative Real-Time Polymerase Chain Reaction Experiments (MIQE) guidelines.\n\n**Option-by-Option Analysis**\n\n**A. Failure to report the amplification efficiency and the slope of the standard curve, precluding assessment and correction for efficiency differences across runs or targets.**\nThe slope of the Cq vs. $\\log_{10}(\\text{concentration})$ plot is used to calculate the amplification efficiency, $E = 10^{-1/\\text{slope}}$. For an ideal reaction with $100\\%$ efficiency ($E=2$), the slope is approximately $-3.32$. The report's claim of a high coefficient of determination ($R^2 \\ge 0.99$) only indicates good linearity, not that the efficiency is optimal. A slope that deviates significantly from $-3.32$ indicates a suboptimal reaction, which will lead to inaccurate absolute quantitation. Furthermore, for relative quantitation comparing the viral target to the host GAPDH gene, assuming that both targets amplify with the same efficiency without verification is a major source of error. The widely used Pfaffl method for accurate relative quantitation requires the specific efficiencies of both the target and reference genes. Thus, omitting the slope and efficiency is a critical failure that prevents assessment of the assay's validity and accuracy for both absolute and relative quantitation.\n**Verdict: Correct.**\n\n**B. Absence of an explicit statement of the dynamic range and the concentration points used to construct the standard curve, increasing the risk that sample Cq values are extrapolated outside the validated linear range.**\nA standard curve is linear and reliable for quantitation only over a specific range of concentrations, known as the linear dynamic range. This range has a lower limit of quantification (LLOQ) and an upper limit of quantification (ULOQ). If a sample's Cq value falls below the Cq of the highest concentration standard, or above the Cq of the lowest concentration standard, its quantity must be determined by extrapolation rather than interpolation. Extrapolation is notoriously unreliable and is not considered a valid quantitative practice. The problem states that $10$-fold serial dilutions were used, but not the starting and ending concentrations. Without knowing the Cq values corresponding to the ULOQ and LLOQ, it is impossible to know if the quantified samples fall within the valid range of the assay. This omission creates a significant risk that the reported viral loads are inaccurate.\n**Verdict: Correct.**\n\n**C. Use of a single unvalidated reference gene (GAPDH) for normalization in infected swab samples without demonstrating its expression stability under infection and treatment conditions.**\nRelative quantitation relies on the fundamental assumption that the reference gene is expressed at a constant level across all samples being compared (e.g., infected vs. uninfected). Glyceraldehyde-$3$-phosphate dehydrogenase (GAPDH) is commonly used, but its expression has been shown to be unstable under various physiological and pathological conditions, including viral infections like SARS-CoV-$2$. If the infection itself alters the expression of GAPDH, using it for normalization will introduce a systematic bias. For example, if the virus causes GAPDH expression to decrease, the calculated relative expression of all target genes will be artificially inflated. MIQE guidelines strongly recommend validating the stability of any proposed reference gene under the specific experimental conditions and advocate for the use of multiple stable reference genes. Using a single, unvalidated reference gene is a major methodological flaw in relative expression analysis.\n**Verdict: Correct.**\n\n**D. Lack of a no-reverse-transcriptase control to rule out genomic deoxyribonucleic acid (DNA) contribution when quantifying ribonucleic acid (RNA) targets.**\nThe assay aims to quantify ribonucleic acid (RNA) targets. The samples are from nasopharyngeal swabs, which contain human cells and thus human genomic DNA (gDNA). While the viral target is RNA, the host reference gene, GAPDH, exists in the human genome. If the primers for GAPDH amplify both the complementary DNA (cDNA) reverse-transcribed from messenger RNA (mRNA) and the contaminating gDNA, the total measured Cq will reflect both sources, leading to an overestimation of the GAPDH mRNA level. This would skew all subsequent normalization calculations. A no-reverse-transcriptase (-RT) control is an essential experiment in which the reverse transcriptase enzyme is omitted; any amplification in this control is attributable to gDNA contamination. The absence of a reported -RT control means that potential gDNA contamination has not been ruled out, compromising the accuracy of host gene quantitation and thus any relative expression data.\n**Verdict: Correct.**\n\n**E. Failure to state the thermal cycler manufacturer and model used.**\nThe MIQE guidelines require reporting the instrument model to ensure transparency and facilitate reproducibility by other laboratories. Different models can have minor variations in performance. However, within a single study where all samples (unknowns and standards) are run on the same instrument, the specific model is not a primary source of *bias* in the quantitative results. The critical parameters like efficiency and linearity are measured directly in the experiment itself. Therefore, while this omission violates a reporting guideline, it is far less likely to cause a direct and significant bias in the reported quantitative values compared to the fundamental errors described in options A, B, C, and D.\n**Verdict: Incorrect.**\n\n**F. Not reporting the CRISPR Cas12a trans-cleavage rate or fluorescence threshold used in the orthogonal assay.**\nThe problem explicitly states that the CRISPR-Cas12a assay was used only as an \"orthogonal check\" for \"concordant positive/negative calls\" and, crucially, \"did not use CRISPR signal for quantitation.\" Since all quantitative data (viral load and relative expression) were derived from the qPCR assay, any details pertaining to the separate, non-quantitative CRISPR assay are irrelevant to the question of bias in the qPCR quantitation.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{ABCD}$$", "id": "4620535"}]}